Hansoh Pharma (3692.HK)

Executive Summary

Hansoh Pharma is a leading Chinese biopharmaceutical company listed on the Hong Kong Stock Exchange (3692.HK), with a strong focus on oncology, central nervous system disorders, anti-infectives, and diabetes. The company operates an integrated model spanning R&D, manufacturing, and commercialization, and has a portfolio of over 20 marketed products and several late-stage pipeline candidates. Hansoh's key assets include aumolertinib (third-generation EGFR TKI) for NSCLC, HS-10296 (a novel ALK inhibitor), and HS-10355 (a CNS asset for depression). The company benefits from China's growing healthcare demand and its established commercial infrastructure, which supports robust revenue growth. However, it faces risks from intense competition in targeted oncology and potential pricing pressures. With a market cap exceeding $30 billion, Hansoh is positioned as a major player in China's biotech landscape, driven by its innovative pipeline and expanding global footprint.

Upcoming Catalysts (preview)

• Q2 2026NMPA approval decision for HS-10296 (ALK inhibitor) in first-line ALK+ NSCLC80% success
• Q3 2026Phase 3 data readout for HS-10355 in major depressive disorder65% success
• Q4 2026Potential out-licensing deal for aumolertinib in ex-China markets50% success